Aldeyra suffers rejection in rare eye cancer due to 'lack of substantial evidence' but seeks use under Expanded Access
The FDA has rejected Aldeyra’s bid for approval in a rare, aggressive type of eye cancer for which the company didn’t conduct any clinical trials …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
